Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin

FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus

The Ubiquitination of Rag A GTPase by RNF152 Negatively Regulates Mtorc1 Activation.

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

The Mammalian Target of Rapamycin in Translation and Folding

Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.

mTORC1 phosphorylates and stabilizes LST2 to negatively regulate EGFR

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Regulation of gastric hormones by systemic rapamycin.

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.

Regulation Of Mtorc1 By The Rab And Arf Gtpases

Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay.

Assembly of mTORC3 Involves Binding of ETV7 to Two Separate Sequences in the mTOR Kinase Domain

Abstract PR02: Structural and Functional Analyses of GATOR1, a Negative Regulator of the Mtorc1 Pathway

Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Crystal structure of the Gtr1p-Gtr2p complex reveals new insights into the amino acid-induced TORC1 activation.

Structural Insight into the Ragulator Complex Which Anchors Mtorc1 to the Lysosomal Membrane

PtdIns3P controls mTORC1 signaling through lysosomal positioning.

Genome-wide CRISPR screens identify ILF3 as a mediator of mTORC1-dependent amino acid sensing

Synthetic Lethality of Combined Glutaminase and Hsp90 Inhibition in Mtorc1-Driven Tumor Cells